Skip to main navigation

Codiak Biosciences

Investor Relations - Top Nav

Our Science
Our Science

Through our proprietary engEx™ Platform, we are harnessing the power of nature’s intercellular communication system to engineer a new class of medicines, exosome therapeutics.
Manufacturing
Pipeline & Programs
Pipeline & Programs

We are utilizing our engEx™ Platform to build a broad pipeline of therapeutic candidates that we believe can have a transformative impact on the treatment of a broad spectrum of diseases, with an initial focus on oncology and neurology.
About Us
About Us

At Codiak, we are working to create a major shift in the development of tomorrow’s medicines through scientific ambition, remarkable ingenuity and determined passion for improving patients’ lives.
Careers
Investors & Media
Investors & Media

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines.

Press Releases

Year

October 1, 2021

Codiak to Present Preclinical Data Demonstrating New Potential Therapeutic Applications of Engineered Exosomes at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Additional Formats

PDF Version

August 18, 2021

Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors

Additional Formats

PDF Version

August 5, 2021

Codiak BioSciences Reports Second Quarter 2021 Financial Results and Operational Progress

Additional Formats

PDF Version

July 7, 2021

Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

Additional Formats

PDF Version

July 6, 2021

Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles

Additional Formats

PDF Version

June 15, 2021

Codiak BioSciences Expands Executive Leadership

Additional Formats

PDF Version

June 2, 2021

Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

Additional Formats

PDF Version

May 20, 2021

Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

Additional Formats

PDF Version

May 11, 2021

New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas

Additional Formats

PDF Version

May 10, 2021

Codiak Appoints Jennifer Wheler, M.D., as Chief Medical Officer

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 21

Join our team of experts working at the forefront of advancing engineered exosomes. Explore Careers

© 2021 All Rights Reserved.

Footer Links

Contact
Privacy Policy
Terms of Use

LinkedIn Twitter